Access to cell and gene therapies lags behind in the Netherlands. A Gilead executive is calling for changes in the system. Investments in innovation are limited compared to the need. It is essential to accelerate the availability of ATMP to patients. The article highlights the need for better support for these therapies. Access to them in the country currently does not meet expectations.